AUSTRALASIA

We supply a diversified portfolio of branded prescription, OTC, consumer and infant nutritional products into Australia and New Zealand. We are one of the largest manufacturers in Australia and our manufacturing site in Melbourne produces certain tablets, liquids and semisolids.

Key Countries

Australia
New Zealand

Contribution to Group revenue

Revenue contribution - by therapeutic category

The Australian pharmaceutical sector was valued at AUD17,7 billion as at 30 June 2018 with flat volume growth.
Aspen was ranked 3rd by volume and 9th by value in the Australian pharmaceutical sector for the year ended 30 June 2018.
Almost one in seven scripts written in Australia is for a product distributed by Aspen.

Source: June 2018 IMS

STATISTICS

Number of products launched:

3

(2017: 4)

IMS value of pipeline as at 30 June 2018 anticipated to be launched in:

0 – 2 years

USD113 million

3 – 5 years

USD11 million

Number of product recalls:

Nil

(2017: 3)

Average staff turnover:

13,0%

(2017: 7,5%)

Number of work-related fatalities:

Nil

(2017: nil)

Number of permanent employees:

Revenue – R’billion	2018	2017 (CER)	% change
Total	5 995	5 888	2
Commercial Pharmaceuticals	4 816	4 658	3
Regional Brands	3 605	3 545	2
Anaesthetics	713	621	15
Thrombosis	21	25	(16)
High Potency & Cytotoxics	477	467	2
Nutritionals	715	772	(7)
Manufacturing-FDF	464	458	1

Note: Commercial Pharmaceuticals revenue by customer geography and manufacturing revenue by place of manufacture